

EXTRA GODIF Newsletter October 2022

Thank you for committing to the GODIF trial!

Dear friends and colleagues,

We hope you are all well.

Data on the first 100 participants in the GODIF trial have been sent to the data monitoring committee (DMC) for the first interim analysis. The first interim analysis is looking at fluid balances, the use of escape procedures, and protocol violations. The DMC has raised a concern about the difference in fluid balance between the furosemide group and the placebo group is smaller than expected. This requires further analysis. There are no concerns according to safety and the inclusion continues.

We encourage you to focus on adhering to the protocol and minimise protocol violations and we advise you to remind or teach your staff about the protocol again. As soon as we have the results from the extra analyses and the DMC's final recommendations for the GODIF trial, we will let you know in a newsletter. Don't hesitate to contact us if you have any questions.

The Coordinating Center is always available on the
GODIF hotline: +45 48 29 67 73
Mail: godif@cric.nu
www.cric.nu/godif/
Kind Regards form the GODIF team
Morten (Sponsor) and Sine (Coordinating Investigator)

All the best,

Morten and Sine

